Neonatal Group B streptococcal sepsis by João Paulo Gonçalves de Vilas-Boas
 
  
  
  
  
DISSERTAÇÃO – ARTIGO DE REVISÃO BIBLIOGRÁFICA 
Mestrado Integrado em Medicina 
 
 
 
Neonatal Group B streptococcal sepsis: a literature review   
 
 
João Paulo Gonçalves Vilas-Boas 
 
 
Orientador  
Prof. Doutora Paula Maria das Neves Ferreira da Silva 
 
  
  
  
  
  
  
 Porto, 2017
  
DISSERTAÇÃO – ARTIGO DE REVISÃO BIBLIOGRÁFICA 
 
 
Neonatal Group B streptococcal sepsis: a literature review   
 
 
  
 
  
  
  
 
João Paulo Gonçalves de Vilas-Boas1  
  
  
Orientador  
Prof. Doutora Paula Maria das Neves Ferreira da Silva2,3,4 
  
 
  
1  
Aluno do 6º ano profissionalizante do Mestrado Integrado em Medicina  
Endereço electrónico: paulovb92@hotmail.com 
ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto   
Endereço: Largo Prof. Abel Salazar 2, 4099-003 Porto   
  
 
2
ICBAS-Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Porto, Portugal.  
3
i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. 
4
IBMC-Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.  
 
 
i 
 
 
 
Abbreviations List 
 
EOS - Early Onset Sepsis 
LOS - Late Onset Sepsis 
VLBW – Very Low Birth Weight 
GBS - Group B streptococcus 
IAP - Intrapartum Antimicrobial Prophylaxis 
CD - Custer of differentiation 
TLR - Toll-Like receptors 
Treg - Regulatory T cell 
SIRS – Systemic Inflammatory Response Syndrome 
GAPDH - Glyceraldehyde 3-Phosphate Dehydrogenase 
qPCR – Quantitative real-time amplification system 
ESBL - Extended Spectrum Beta-Lactamase 
pPROM - Preterm Premature Rupture of Membranes 
NAAT - Nucleic Acid Amplification Test. 
 
 
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
ii 
 
 
 
 
ACKNOWLEDGEMENTS 
 À Dra. Paula Maria das Neves Ferreira da Silva, pela disponibilidade e generosidade em 
aceitar a orientação científica deste trabalho e pelo apoio na sua realização. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
ABSTRACT  
 In the early 1970s, Streptococcus agalactiae, or Group B Streptococcus, emerged as a 
major pathogen for newborns. Since then, in most industrialized countries, this bacterium has 
been considered the leading cause of severe neonatal diseases, namely pneumonia, sepsis 
and meningitis. Neonatal Group B Streptococcus infections are prevented by intrapartum 
administration of antibiotic prophylaxis to mothers of children at risk of developing early 
diseases. This strategy has diminished the prevalence of early onset neonatal sepsis. However, 
there are concerns about the potential generation of antibiotic resistance, drug-induced adverse 
reactions and the negative impact on the gut microbiota, inducing dysbiosis. Moreover, mortality 
remains high, particularly in premature and very low birth weight infants and 50% of the 
neonates that survive to infection present neurological sequels.    
Recently studies have been offering a better understanding of the ontogeny of the 
human immune system, which is essential for the development of efficient and safe 
interventions aiming at providing protection to neonates against pathogens. Also, several 
researches have been done for the identification of new markers for neonatal sepsis diagnosis 
and prevention. This search for an ideal sepsis biomarker (with high sensitivity and specificity) it 
is important for the diagnosis to be made accurately and mainly at the earliest possible, which 
allow for the use a more selective antibiotic therapy. Moreover, there is a need for the 
standardization of pediatric sepsis definition that is essential for a better awareness and 
management of this disease. Therefore, in this article, a literature review of Group B 
Streptococcus neonatal sepsis is presented and discussed by using the published studies from 
the last ten years by search in PubMed- MEDLINE database, focusing on the issues mentioned 
above and others relevant to the topic.  
This review show that although there has been a considerable increase in knowledge of 
neonatal sepsis induced by Group B Streptococcus, further researches are needed to develop a 
new preventive approaches and new diagnosis markers, to improve the outcomes of this 
devastating disease.  
 
 
KEY-WORDS  
 Neonatal sepsis; Group B Streptococcus; Streptococcus agalactiae, infection; 
neonatology; intrapartum antibiotic prophylaxis; diagnosis; prevention; management. 
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RESUMO 
 No início da década de 70 do século passado, o Streptococcus agalactiae, também 
designado de Estreptococos do grupo B, emergiu como um importante agente patogénico nos 
recém-nascidos. Na maioria dos países industrializados, esta bactéria tem vindo a ser 
considerada a principal causa de doenças neonatais graves, como pneumonia, sépsis e 
meningite. As infeções neonatais por Estreptococos do grupo B são atualmente prevenidas 
pela administração antibiótica intraparto. Esta profilaxia diminuiu consideravelmente a 
prevalência de sépsis neonatal. Contudo, vários problemas têm vindo a ser apontados com o 
uso de antibióticos como por exemplo, o desenvolvimento de resistências a agentes 
antimicrobianos, reações adversas induzidas pela administração, o impacto negativo sobre a 
flora intestinal ocasionando alteração do microbiota (disbiose). Além disso, a mortalidade 
infantil causada pela infecção por esta bactéria permanece alta, particularmente em recém-
nascidos prematuros e de muito baixo peso. Mais ainda, cerca de 50% dos neonatos que 
sobrevivem à infeção ficam com sequelas neurológicas permanentes. 
 Estudos recentes têm trazido mais conhecimento sobre a ontogenia do sistema 
imunológico humano. Este conhecimento é essencial para o desenvolvimento de intervenções 
eficazes e seguras nos recém-nascidos de modo a torna-los protegidos contra os agentes 
patogénicos. Além disso, várias pesquisas foram realizadas com o objetivo de identificar novos 
marcadores para o diagnóstico e prevenção da sépsis neonatal. A procura de um biomarcador 
de sépsis com alta sensibilidade e especificidade é essencial para que o diagnóstico seja feito 
com maior precisão e o mais cedo possível, o que permitirá o uso de uma antibioterapia mais 
seletiva. Além disso, há uma necessidade de padronização da definição de sépsis pediátrica de 
modo a que haja um melhor reconhecimento e gestão desta patologia. Neste artigo, estes e 
outros aspectos importantes da sépsis neonatal por Estreptococos do grupo B serão 
apresentados e discutidos, através de uma revisão da literatura, usando o motor de busca de 
livre acesso à base de dados MEDLINE, o PubMed, para escolher os artigos publicados nestes 
últimos 10 anos sobre este tema.  
 Esta revisão mostra que embora nos últimos 10 anos tenha havido um aumento 
considerável no conhecimento acerca da sépsis neonatal induzida pelo Estreptococos do grupo 
B, é ainda necessário mais investigação sobre este tema, de modo a desenvolver-se novas 
abordagens preventivas e novos marcadores de diagnóstico contra esta doença que ainda é 
tão devastadora.  
 
PALAVRAS-CHAVES 
Sépsis neonatal; Estreptococos do grupo B; Streptococcus agalactiae; infeção; neonatologia; 
profilaxia antibiótica intraparto; diagnóstico; prevenção; tratamento. 
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1. Introduction 
Neonatal sepsis is one of the leading causes of neonatal mortality and morbidity 
worldwide, representing a serious public health problem associated with low survival rates and 
potential long-term sequelae [1]. Management is far from being optimal due to a challenging 
diagnostic and therapeutic limitation and therefore efforts are mainly focused on prevention. 
Group B streptococcus (GBS) is the main agent responsible for neonatal sepsis and meningitis 
[2], which led to many developed countries to adopt GBS maternal screening and intrapartum 
antibiotic prophylaxis (IAP). Despite a significant decrease in neonatal sepsis rates in the last 
decades, IAP efficacy is not absolute, and it has been pointed out several limitations and 
disadvantages [3-6]. To improve the outcomes of this devastating disease in future, it is 
important to review and discuss all the knowledge gathered until now. Therefore, the aim of this 
study is to present a literature review about the subject: neonatal Group B streptococcal sepsis. 
Topics like epidemiology, etiology, pathophysiology, IAP, diagnosis and treatment will be 
presented and discussed. 
 
2. Methods 
 Research Strategy and Selection Criteria: a systematic literature search in PubMed-
MEDLINE was done using the studies published from January 2007 to May 2017. Keywords 
used were: GBS, Streptococcus agalactiae, sepsis, neonates, intrapartum antibiotic 
prophylaxis, fetal immune system and neonatal sepsis treatment. Medical text books such as 
Nelson’s Textbook of Pediatrics and Harrison's Principles of Internal Medicine, and some 
articles published before 2007 but considered relevant to this subject, were also included. In 
total, 92 articles were used on this review. We excluded case reports, low quality studies and 
conference meeting abstracts. 
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3. Epidemiology and Etiology  
Neonatal sepsis refers to a systemic  infectious condition in neonates, associated with 
hemodynamic changes and other clinical manifestation with a high morbidity and mortality 
impact [7]. It is estimated that 36% of all deaths in the neonatal period (≤ 28 days of life) are due 
to invasive infections [8]. If term infants were considered separately, neonatal sepsis accounts 
for 15,6% of all causes of neonatal death (annex 1), while if only preterm infants are evaluated, 
sepsis is responsible for approximately 20% of all deaths [9]. Infection rates vary from 1-5 to 49 
per 1000 live births [10], depending on both maternal and infant geographical associated risk 
factors, and medical resources distribution. 
According to symptom’s presentation timing, it is possible to distinguish between early 
onset sepsis (EOS) and late onset sepsis (LOS). EOS is defined as the onset of sepsis within 
72 h of postnatal life, while LOS has been defined as the onset of sepsis between 3-7 days  of 
life [7]. This distinction is relevant because EOS and LOS reflect different etiologies and 
pathophysiology processes. EOS is caused by bacterial pathogens transmitted vertically, while 
LOS is considered to be transmitted by both vertically and horizontally [7].  
 
 3.1 Early Onset Neonatal Sepsis 
Nowadays, EOS has an estimated prevalence of 0,7-1 per 1000 live-births in developed 
countries that adopted guidelines for intrapartum antibiotic prophylaxis (IAP), such as the United 
States [8]. Despite a significant decrease on prevalence of this disease after IAP introduction 
[14], it still remains a serious post-partum period complication, with mortality rates averaging 
11% [8]. Moreover, both incidence and mortality are notably higher in very low birth weight 
(VLBW) preterm infants [11].  
EOS pathogens are typically maternal vaginal flora´s commensals, who colonize the 
newborn during its passage through the birth canal or, in a minor case, by ascending to 
amniotic fluid or placenta, causing in-utero infection [12]. The organisms most frequently 
involved are GBS and Escherichia coli, and account for more than 70% of all cases [11]. Other 
bacterial pathogens like Staphylococus aureus, Enterococus spp., other streptocci, 
Haemophilus influenza, Listeria monocytogenes, and fungal pathogens such as Candida spp, 
are also involved [43]. VLBW infants are more likely to have sepsis from Gram-negative 
organisms [13]. Viral pathogens are not typically associated with an EOS presentation, and 
must be distinguished from bacterial sepsis [11].  
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Half of the newborns born from GBS colonized mothers will also be colonized at time of 
birth, however the large majority of them are asymptomatic, and only 2% have evidence of 
sepsis [8]. After IAP implementation in the United States, GBS EOS incidence reduced 
substantially [14].  
GBS still remains the most common EOS etiologic agents, especially in term infants. 
However, the decrease in GBS sepsis rates due to IAP has shifted the focus to Escherichia coli 
[3]. This bacterium is more lethal than GBS [11]. Some epidemiological studies, show that E. 
coli EOS incidence rates remained similar in spite of IAP guidelines [15], while others report 
increased incidence of E. coli EOS, particularly among VLBW infants [16]. Despite these 
different results, it is consensual that there is an increase in EOS due to ampicillin-resistant E. 
coli [8]. Since ampicillin is one of the first line agents for neonatal sepsis´s empirical treatment, 
higher resistance rates are worrisome. Moreover, E. coli is the most common EOS etiologic 
agent in preterm and VLBW infants [9]. Preterm infants with EOS were shown to have a higher 
mortality rate than preterm infants with LOS, with E. coli causing the highest mortality rate [13]. 
 
 3.2 Late Onset Neonatal Sepsis 
The incidence of neonatal LOS is inversely related to neonatal gestational age and birth 
weight, and varies geographically from 0.61% to 14.2% among hospitalized newborns [7, 17]. 
LOS is a common complication of the preterm newborn with prolonged hospitalization, due to 
the use of invasive procedures and devices such as mechanical ventilation and intravascular 
catheters, which allow for invasive disease caused by nosocomial acquired microorganisms. 
The advances in neonatal intensive care have improved the survival of neonates but led to an 
increased rate of LOS [17]. 
Gram-positive bacteria are responsible for most of LOS cases (~70%) [8, 10]. Other 
possible pathogens are Gram-negative bacteria (18-25%), and fungi (5-12%) [8, 10]. Regarding 
Gram-positive bacteria, the most common etiologic agent is the coagulase negative 
staphylococci. GBS accounts for only 5% of all cases [18]. Staphylococcus aureus is more 
common in neonates with vascular-access catheters [7]. Deaths attributed to LOS increase with 
postnatal age, 36% in newborns aged 8–14 days, and 52% in those aged 15–28 days [19]. 
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4. Pathophysiology 
 4.1 Neonatal Sepsis Risk Factors  
 Risk factors for EOS can be grouped into maternal and infant risk factors. Maternal risk 
factors include invasive procedures applied during pregnancy such as amniocentesis, as well as 
impaired maternal immunological function and poor maternal nutrition [11]. Labor risk factors 
are also considered. Maternal fever and prolonged rupture of membranes (more than 18 hours 
prior to delivery), increases EOS risk to 1% [20]. Chorioamnionitis leads to a 1-4% EOS 
incidence, due to swallowing of infected amniotic fluid by the fetus. Longer length of labor, 
amniotic membrane rupture, and internal placement of fetal or uterine devices are also 
associated with a higher chorioamnionitis risk [21]. Infant related EOS risk factors consist of 
prematurity, low birth weight, APGAR scores ≤6 in the first five minutes [11], and male sex, 
since in the presence of a male fetus the trophoblast has the potential to generate a more pro-
inflammatory environment [22]. Preterm low birth weight infants have a 3 to10 higher incidence 
of infection than full-term normal birth weight infants [7]. Premature infants usually present low 
maternal IgG levels and diminished skin and mucous membrane barrier function, which can be 
further exploited in ill infants with invasive procedure needs. 
 Main LOS risk factors were already described. Moreover, extended stay in the 
healthcare environment and formula feeding can disturb the normal gut colonization process, 
which could facilitate bacterial translocation into the bloodstream [23]. However, despite 
theoretically promising, meta-analysis studies showed that probiotics not significantly reduce 
sepsis incidence [24]. It has been demonstrated that human milk feeding is associated with a 
threefold reduction of LOS risk [25].  
 Regarding specific risk factors for GBS EOS, the most important is maternal intrapartum 
GBS colonization. 10-30% of pregnant women are estimated to be colonized with GBS, and if 
IAP is not implemented, around 1-2% of infants born from these mothers will develop EOS [14]. 
The gastrointestinal tract serves as the primary reservoir for GBS and is the likely source of 
vaginal colonization. Additional risk factors are GBS bacteriuria, a history of a previous child 
born with GBS infection and low maternal serum IgG antibodies tiers against specific GBS 
capsular polysaccharides [14].   
     
5 
 
 4.2. Newborn´s immune system  
 4.2.1. Neonatal immune system development     
It is crucial to understand the immunological events behind neonatal sepsis in order to 
improve diagnostic tools and therapeutics approaches that will lead to a better outcome. Multi-
parameter of flow cytometry combined with mass spectrometry and other technologies have 
been used to study the ontogeny of the immune system [26].  
Newborns are usually considerably immunocompromised because the immune system 
is immature with broad deficits across both innate and adaptive immune functions [26]. 
However, it is not advisable to presume that the immune response in fetuses, newborn and 
infants is simply hypofunctional or underdeveloped [26]. It is better to consider the immune 
system of neonates as functionally distinct of the adult counterpart, and is important to 
remember that the survival of the allogenic fetus in the uterine microenvironment depends on 
the maternal and fetal immune tolerance [27]. 
Regarding the gestational development of specific cell populations, neutrophils are an 
important effector cell in newborn protection against pathogens as the bacterium GBS. 
However, neutrophils numbers are relatively low until 32 gestational weeks, and preterm 
newborns lack functional neutrophil extracellular traps and effective generation of potent 
reactive oxygen species [26]. In this regard, cases of early-onset GBS sepsis are usually 
characterized by a low number of neutrophils, and impaired neutrophil recruitment, with 
reduced adhesion capabilities [28]. Thus, qualitative and quantitative neutrophils deficiencies 
may contribute for the increased susceptibility of neonates to sepsis.  
Complement system is also impaired in neonates born prematurely [29], as well as the 
ability to produce high amounts of antibodies against T-independent antigens, which impairs 
response against encapsulated bacteria, such as GBS [30].  
T-cell function is more deviated to favor a Th2 response than Th1´s, leading to 
decreased CD8+ T-cell cytotoxic activity and an increased T-regulatory (Treg) cell population 
[31]. Lack of immunological memory and exclusive reliance on maternal antibodies also 
contribute for the high susceptibility of neonates to microbes.  
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 4.2.2. Fetal Immune Tolerance  
One of the unique characteristics of the developing fetal immune system is its ability to 
maintain a tolerant state to prevent a response against maternal and self-antigens. This is 
accomplished by an increased Treg cells frequency in fetal tissues, composing 15-20% of all 
CD4+ cells in fetal lymphoid tissues [32]. While essential for fetal development, this 
predisposition of fetal cells to differentiate into Treg cells is accompanied by an overall tolerant 
state that leads to an increased susceptibility to microbes. Despite this tolerant state, preterm 
infants show an enhanced production of pro-inflammatory cytokines compared to adults when 
invaded by a pathogenic microorganism, which often leads to a systemic inflammatory 
response syndrome (SIRS) [33].  
IL-10 is one of the most important immunosuppressive and anti-inflammatory 
molecules in pregnancy [27]. It has been showed that neonates are committed to produce IL-
10 and this could be used by GBS to survive in the host [30]. GBS produces an extracellular 
virulence factor, called glyceraldehyde 3-phosphate dehydrogenase (GAPDH) that induces a 
rapid IL-10 production by the host [34].  High levels of IL-10 impair neutrophil recruitment into 
infected organs, preventing bacterial clearance. Therefore, IL-10 production very early after 
GBG infection allows bacterial immune evasion. This is supported by results showing that IL-
10 blocking trough anti-IL-10R monoclonal antibodies (mAB) administration confers protection 
of neonates  to bacterial challenge [30].  
 
 4.3 GBS virulence factors 
GBS encodes virulence factors for adherence, invasion and colonization of host 
tissues. Examples include a polysaccharide sialic acid rich capsule and pore-forming toxins 
[35]. GBS colonizes maternal genital and lower gastrointestinal tract as a commensal 
microorganism, but also acts as an invasive pathogen in other tissues. Therefore, this 
bacterium is able to adapt to different hosts environments by regulating its virulence factors. 
Understanding how GBS regulates virulence factors expression could be useful in the 
development of new selective therapeutic targets to replace the IAP administration. Pore-
forming toxins promote pathogen entry into host´s cells, allowing for intracellular survival and 
systemic dissemination [35].  
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A sialic acid-rich capsule prevents the host´s immune system to recognize GBS as 
nonself, restraining C3 complement factor deposition and phagocytosis [36]. Studies have 
also demonstrated that this polysaccharide capsule encoded by GBS can be modified by O-
acetylation, changing the host´s antibody response recognition against GBS´s capsular 
antigen [35]. This bacterium also encodes a superoxide dismutase, and a C5a peptidase that 
impairs neutrophil recruitment [36]. Serine proteases produced by GBS cleave extracellular 
matrix components and allows for host´s immunity system evasion. Strains cold shock protein 
(CspA) defective have a diminished virulence [37]. Pili mediate resistance to cationic 
antimicrobial peptides and allows attachment to host cells. GBS strains lacking PilB 
demonstrate decreased virulence [38].  
 
4.4 Neonatal Sepsis 
 4.4.1 Systemic Inflammatory Response Syndrome   
 Systemic inflammatory response syndrome (SIRS) can be broadly defined as the 
systemic manifestations that result from an uncontrollable, dysregulated immune response, 
being sepsis a SIRS response in the context of a proven microbiological infection. While there 
were numerous attempts to give an objective definition to SIRS, sepsis, severe sepsis and 
septic shock in pediatric population, this has been proven difficult, especially for preterm 
newborns. Goldstein, Giroir et al. reported listed criteria for pediatric sepsis in both newborns 
and neonates but, preterm infants were excluded from this definition [39]. Key developmental 
differences modulate neonatal sepsis pathophysiology, and so age is a variable that strongly 
affects the underlying immune status and response to therapy. Standardization for sepsis 
criteria to all newborn is difficult, leading ultimately to a high reliance on the physician´s 
clinical suspicion, which has a significant positive predictive value, superior than 70% [40]. 
 The major difference in pediatrics SIRS criteria, when compared to adult´s is that 
pediatric SIRS require temperature or leukocytes alterations to be present [39].  
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*Adapted from Goldstein  B,  Giroir  B,  Randolph  A,  International  Consensus  Conference  on Pediatric S. 
International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics, 2005 
 
Sepsis´s pathophysiology is not yet completely understood. An inflammatory stimulus, 
such as a bacterial toxin, triggers production of proinflammatory mediators, including TNF- 
and IL-1. These cytokines cause neutrophil–endothelial cell adhesion, clotting activation, and 
microthrombi formation. They also lead to other molecular mediators release, including 
leukotrienes, lipoxygenase, histamine, bradykinin, serotonin  and IL-1 [41]. There is an 
overactivation of the innate immune system. Although some patients die during the initial, 
hyperinflammatory phase of sepsis, most patients perish later, in association with an 
immunosuppressive state [31]. Immune response to pathogens also induces an anti-
inflammatory endogenous response, mediated by both cytokine antagonists and cytokines 
with anti-inflammatory proprieties (annex II). This anti-inflammatory compensatory response 
may play a greater role in septic shock´s pathophysiology in children, when compared to 
adults [31]. 
 
 
Table 1 - Definitions of systemic inflammatory response syndrome, sepsis, 
severe sepsis and septic shock in pediatrics* 
SIRS 
Presence of at least two of the following four criteria, one of which must be abnormal temperature or 
leucocyte count: 
• Core Temperature of > 38,5ºC or <36ºC 
• Heart Rate < 10th percentile for age (children <1 year only) or > 2 SD 
• Mean Respiratory Rate > 2 SD or mechanical ventilation for an acute process 
• Leukocyte count elevated or depressed for age or > 10% immature    neutrophils 
Sepsis 
SIRS in the presence of or as a result of suspected or proven infection 
Severe Sepsis 
Sepsis associated with cardiovascular dysfunction, acute respiratory distress syndrome or two or 
more organ dysfunctions 
Septic Shock 
Sepsis and cardiovascular organ dysfunction 
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4.4.2 Neonatal Septic Shock  
Regarding septic shock’s pathophysiological features, initially arteries and arterioles 
dilate, decreasing peripheral arterial resistance and cardiac output typically increases. This 
stage has been referred to warm shock. Later, catecholamine production and release 
becomes insufficient to maintaining cardiovascular system´s homeostasis, due to apoptosis of 
adrenal medullary cells [42]. Cardiac output may decrease, BP falls (with or without an 
increase in peripheral resistance), and typical features of shock appear. Bradycardia may be a 
sign of SIRS in the newborn age group but not in older children, in whom it is a terminal event 
[39]. There are several developmental differences in hemodynamics, coagulation cascade, 
and inflammatory response to sepsis, alongside the already mentioned immune response in 
pediatric population that differentiates pediatric sepsis from adult sepsis.   
Hypovolemia, either absolute or relative, is the most common cause of shock in 
children. Abnormalities in peripheral overregulation and/or myocardial dysfunction likely play a 
greater role in the hemodynamic derangements associated with pediatric septic shock in 
neonates and young infants [31]. Myocardial depression is a common pathophysiological 
feature in pediatric septic shock, due to the developmental differences in infant’s myocardial 
structure, compared to adults. Infants have a limited capacity to increase stroke volume during 
stress, and so neonates and young infants are more dependent on an increase in heart rate to 
generate increased cardiac output, which is difficult, due to newborns’ relatively higher 
baseline heart rate [31].  
Coagulopathy may develop because of intravascular coagulation with consumption of 
major clotting factors and excessive fibrinolysis. Microvascular thrombosis contributes, 
alongside vascular tone dysfunction, to end-organ dysfunction. The physiologic homeostatic 
balance of anticoagulants versus procoagulant factors is biased towards procoagulation with 
defective anticoagulation, favoring microvascular thrombosis, and also bleeding diathesis. 
There is also depletion of natural anticoagulants [42].  
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Table 2- Cardiovascular dysfunction criteria* 
 
*Adapted from Goldstein  B,  Giroir  B,  Randolph  A,  International  Consensus  Conference  on Pediatric S. 
International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics, 2005 
 
 
5. Neonatal Sepsis GBS prophylaxis  
 5.1 Intrapartum Antibiotic Prophylaxis  
To this date, receiving parenterally antibiotics during labor is the only proven strategy to 
protect a newborn from early-onset group B strep disease [14]. Previous to guidelines 
implantation, series reported 1,8/1000 live births with early-onset GBS sepsis, while nowadays 
rates vary around 0,35-0,41/1000 live births in most developed countries [43]. 
Introduction of generalized use of IAP was met with concern that sepsis presentation in 
the newborn could be masked. However, further studies showed that there was no difference in 
sepsis clinical presentation between neonates exposed to intrapartum antibiotics and those who 
not [44]. Despite high compliance rates for prenatal screening and intrapartum antibiotics in 
western countries, there are still missed opportunities, and most early-onset group B 
streptococcal disease in recent years occurs in newborns of prenatally GBS-negative mothers 
[45]. Therefore, it is necessary additional measures to prevent neonatal GBS infection. This gap 
between maternal colonization status and newborn´s sepsis at the onset of labor, seems to be 
responsible for most of the disease burden in countries with a high screening compliance rate. 
Early-onset neonatal GBS disease has remained stable in the last decade, without further 
decrease [46]. 
 
Despite administration of isotonic intravenous fluid > 40 ml/Kg in 1 hour, any of the following: 
Need for vasoactive drug to maintain BP in normal range 
Decrease in BP < 5
th
 percentile for age or systolic BP <2 SD below normal for age 
Two of the following: 
 Unexplained metabolic acidosis 
 Increased arterial lactate  
 Oliguria: Urine output < 0,5 ml/Kg/hr 
 Prolonged capillary refill: >5 sec 
 Core to peripheral temperature gap > 3ºC 
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 5.2 New Prevention Strategies 
Despite the success of prenatal screening test in decreasing GBS infection in neonates, 
it has a lower predictive positive value compared to GBS screening during labor. This could be 
prevented by performing the microbiological cultures closer to the delivery date, but even then, 
positive predictive value will not probably be as high as when  GBS screening is done during 
labor [45]. To address these problems, nowadays investigation is focused in rapid testing 
methods to quickly evaluate the need for IAP during delivery, as well as in primary prevention 
with the use of a maternal vaccine against most common GBS serotypes [11]. The most 
promising method for rapid intrapartum screening is RT- PCR, based on GBS DNA. It can yield 
results in 45 minutes, much faster than the results obtained with microbiological cultures [47]. 
However, it is not used in routine clinical practice, due to the cost, availability and contamination 
potential. Other molecular assays do not have sufﬁcient sensitivity to replace microbial cultures, 
but are useful as adjunctive tests [65]. 
Currently there is no maternal vaccine that protects newborns from GBS invasive 
disease. Research continues, since vaccination has several advantages over IAP. Decreasing 
antibiotic use will lead to lower risk of resistant GBS strains and also to a decrease in Gram-
negative infections rising prevalence. Since GBS serotypes differ dramatically around the world 
[11], it would be more beneficial to use a vaccine against an antigen not specifically associated 
with a serotype. Vaccination would theoretically prevent a small but significant percentage of 
preterm births and more than half (60-70%) of neonatal GBS infection [48]. Despite all this 
potential of new prevention strategies, the importance of clean delivery practices and 
handwashing during delivery cannot be omitted. There is strong evidence that this approach 
decrease neonatal sepsis in both home and health facility settings [49].  
 
5.3 Timing of screening and Intrapartum Antibiotic Prophylaxis 
recommendations  
GBS colonization status is not definitive and changes during pregnancy. Therefore, it is 
advisable to assess bacterial colonization in late pregnancy in all pregnant women. Ideally 
screening should be done between 35th - 37th gestational weeks, allowing late third trimester 
colonization status to be used as a surrogate marker for intrapartum colonization [14]. An 
exception can be made in women with either asymptomatic or symptomatic GBS bacteriuria at 
any time during pregnancy, or in women who had a previous infant with invasive GBS disease.  
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In these situations, late trimesters screening is not needed and pregnant women should 
receive intrapartum antibiotic prophylaxis to prevent early-onset GBS disease. Colonization 
early in pregnancy is not predictive of early-onset GBS disease [14].   
A culture-based screening approach was proven to more efficient in decreasing the 
burden of neonatal disease compared with previous used risk based IAP [11]. Risk-based 
method identified suitable candidates for intrapartum chemoprophylaxis accordingly to the 
presence of intrapartum risk factors. Specimen collection should be done with swabbing of both 
the lower vagina and rectum in order to increase culture yield. Antimicrobial susceptibility testing 
of GBS isolates could be important, especially in penicillin-allergic woman, which alternative is 
clindamycin, an antibiotic associated with increasing resistance among GBS isolates [14].  
The timing of prenatal GBS screening may have the largest effect on its Positive 
Predictive Value [11]. Woman who were not screened during pregnancy, who deliver shortly 
after GBS screening, or who culture results are not available at the time of delivery, should be 
managed according to the presence of intrapartum risk factors. IAP is recommended for 
unknown GBS status at the onset of labor and any of the following signs: delivery at <37 weeks’ 
gestation; amniotic membrane rupture ≥18 h; intrapartum temperature ≥38.0°C; intrapartum 
NAAT positive for GBS [12]. Management for GBS prophylaxis in women with preterm rupture 
of membranes can be consulted in annex III. Table 3 shows the theoretical reduction in GBS 
EOS among different prevention strategies. 
  
 
*Adapted from Royal College of Obstetricians and Gynecologists (2003). Prevention of early onset neonatal group B 
streptococcal disease. Clinical Practice Guideline No. 36. 
 
 
Table 3 - Prevention Strategies for Group B Streptococcus Early Neonatal Sepsis* 
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5.4 Antibiotic selection for Intrapartum Antibiotic Prophylaxis 
Penicillin is the first line agent used for GBS chemoprophylaxis therapy, both in mothers 
with positive prenatal GBS screening tests, and mothers with unidentified GBS status [14]. 
Ampicillin is an acceptable alternative. There is a rare possibility for severe allergic reaction that 
will require an emergency approach, and woman with history of anaphylaxis or angioedema, 
after receiving penicillin or cephalosporin should receive vancomycin or clindamycin for IAP 
[14]. If penicilin-alergic, but without a history of this serious reactions, cefazolin is the preferred 
agent, because its activity is similar to first-line agents, with the advantage of not having 
documented resistances [36]. When clindamycin for IAP is indicated, susceptibility antimicrobial 
testing should be performed before on prenatal GBS isolates. Whether this is not possible, 
vancomycin is the agent of choice in allergic penicillin mothers with history of serious allergic 
reactions [14]. Antibiotics should be administered parentally for IAP since oral administration 
has no beneficial effect. Administration should occur during labor, and not before, since there is 
no complete bacteria eradication, and multiplication can occur quickly.  
 
 
Figure 1 - CDC-recommended regimens for intrapartum antibiotic prophylaxis for 
prevention of early-onset GBS disease 
Adapted from Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. 
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5.5 Intrapartum prophylaxis´s potential adverse effects 
After IAP introduction an increase in relative neonatal sepsis incidence due to non-GBS 
microorganisms, as well as an increase in the incidence of various pathogens resistant to 
antibiotics, specifically to ampicillin have been observed [3]. In VLWB infants, studies identified 
an increasing number of Candida spp infections and Gram-negative infections. Among Gram-
negative infection, one study documented increase in the ampicillin resistance of E. coli strains 
[4]. 
Use of intrapartum ampicillin or penicillin can be considered an independent risk factor 
for ampicillin/penicillin resistance among late-onset infections, doubling the risk of antibiotic 
resistance [4]. Despite IAP use, LOS incidence has not decreased and IAP has led to increase 
in erythromycin and clindamycin resistant GBS isolates [4]. Another potential threat of IAP is 
intestinal disbiosis. Epidemiological studies found an association between antibiotic usage in 
early infancy and occurrence of various autoimmune diseases, such as diabetes, and asthma, 
as well as obesity and allergic and atopic diseases [5].  This could be linked to the short term 
and long term effects of antibiotics in the diversity and composition of the gut flora, which can 
have implications in the immune system development. According to a prospective study in 
infant´s gut microbiota characterization in children born from mother´s who received IAP, at 3 
months of age present signiﬁcant alterations in the overall microbiota with reduction in 
microbiota richness and diversity [6]. 
 
6. Clinical Presentation 
Both EOS and LOS clinically present as an ill-defined, highly variable, unspecific group 
of symptoms. Severity is also diverse. Clinical diagnosis is difficult, particularly in preterm and 
low birth weight infants due to their undeveloped immune system that leads to a misleading 
clinical picture [11]. General nonspecific symptoms include alterations in feeding behavior, 
which occurs early in the disease course, lethargy, poor cry and pale skin [10, 50]. Fever, 
hypothermia or a normal body temperature can all be present, however it is more common for 
a septic infant to be hypothermic [10, 11].  Fever is usually associated with low birth weight 
babies or babies born to a febrile mother [3, 45]. Nonspecific signs that may be present are 
anuria, metabolic acidosis, hypoglycemia or hyperglycemia [3, 45]. Signs such cyanosis, 
apnea, tachycardia, bradycardia and hypotension are associated with hemodynamic instability 
and may precede a hypotensive shock [50].  
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The physician must be aware that all organs and systems can be affected , being the 
respiratory system one of the most commonly involved, as pneumonia is often the presenting 
infection [11]. Respiratory distress, a common finding in this setting can masquerade 
congenital disorders such as congenital heart disease or congenital diaphragmatic hernia. 
Also, any noninfectious inflammatory syndrome can mimic the signs and symptoms of 
neonatal sepsis [51]. Clinical suspicion is of utterly importance for diagnosis. 
 
 
Table 4 - Initial Signs and Symptoms of Infection in Newborn Infants* 
Cardiovascular System 
Pallor; cold skin; sweaty skin 
Tachycardia 
Hypotension  
Bradycardia 
Respiratory System 
Apnea, dyspnea 
Tachypnea 
Retractions 
Cyanosis 
Renal System 
Oliguria  
Gastrointestinal System  
Abdominal Distension 
Vomiting 
Diarrhea 
Hepatomegaly 
Central Nervous System 
Irritability, lethargy 
Tremors, seizures 
Hyporeflexia, hypotonia 
Abnormal Moro reflex 
Full fontanel 
Hematologic System 
Jaundice 
Splenomegaly 
Pallor 
Petechia, purpura 
Bleeding 
 
*Adapted from  Enrione M, Powel K. Sepsis, Septic Shock, and Systemic Inflammatory Response Syndrome. 
Kliegman R. Nelson’s Textbook of Pediatrics (20
th
 Ed.). Saunders, 2016) 
  
Unfortunately, etiologic suspicion based solely on clinical findings and signs, is not 
possible. A few signs and symptoms, and their association, are more frequently associated 
with certain pathogens, such as a cutaneous erythematous rash associated with Candida spp, 
or Gram-negative other than E. coli [7].        
 Regarding long term complications, EOS is associated with an increased risk of 
bronchopulmonary dysplasia in preterm infants as well as neurodevelopment delay and other 
neurologic complications. However, these associations are very often confounded by multiple 
factors, such as the prematurity degree. Term infants who are affected by GBS infection also 
have a high complication rate. A significant percentage will suffer neurologic sequela, such as 
seizures, blindness and deafness and cognitive delays [11].  
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7. Diagnosis and Laboratory Markers 
 7.1 Initial Workup 
It is not advisable to wait for the results of the blood cultures to initiate the treatment 
when neonatal sepsis is suspected, since it takes 24-48 hours. Bacterial isolation from blood 
is the gold standard for sepsis diagnosis [1]. It is recommended to perform at least two blood 
cultures, one percutaneous and one for each vascular access. Earlier therapeutic intervention 
is of the most importance to warrant lower mortality and morbidity associated rates. 
Laboratory results should be obtained as soon as possible to guide initial management.  
Optimal results require culturing of 6 mL of blood, which is not feasible [1]. A minimum 
of 0,5-1 mL is advisable [7]. Blood cultures are not sensible enough to exclude sepsis and 
false positive cases can occur due to asymptomatic bacteremia or contamination. Positive 
cultures range from 8-73% in the diagnosis of potential neonatal sepsis [50], thus there is a 
high need for the use of non-culture dependent methods and other supplemental tests (annex 
IV). Laboratory tests are helpful in guiding antibiotic treatment, avoiding unnecessary 
treatment of non-infected neonates and thus unnecessary emergence of multidrug resistant 
organisms. Typical sepsis workup consists of obtaining a complete white blood count, with 
differential leucocyte count analysis, urine cultures, and a lumbar puncture for cell count and 
culture. Acute phase reactants, such as C-reactive protein (CRP), and procalcitonin (PCT) 
also assist in the diagnosis. Image testing, such as thoracic x-ray, is considered when 
respiratory signs and symptoms are present. Tracheal aspirate culture is also potentially 
indicated in intubated newborns with suspected sepsis [11]. Despite meningitis incidence in 
bacteremia infants being up to 23% [51], the need of lumbar puncture to rule out meningitis in 
infants with suspected sepsis is controversial. In the high-risk, healthy-appearing infant, data 
suggests that the likelihood of meningitis is extremely low. Lumbar puncture should be 
performed in presence of a negative blood culture in infants whose clinical course or 
laboratory data strongly suggest bacterial sepsis, or infants whom initial antimicrobial therapy 
didn´t improve their clinical state [51].  
Urine testing is not needed in neonates with suspected sepsis in their first few days of 
life because most urinary tract infections in this age group are secondary to hematogenous 
dissemination to the kidney by bacteremia, and so urine analysis wouldn’t add more useful 
information that the one provided by blood cultures [51]. However, urinalyses and urine 
culture should be considered for subsequent workups in neonates who remain symptomatic, 
especially in LOS [52].  
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 7.2 Complete blood count 
Total and differential white blood cell count, absolute neutrophil count, and immature to 
total neutrophil ratio are generally used for neonatal sepsis screening [7].  On their own, none 
of these tests is sensible nor specific enough to accurately identify or exclude neonatal sepsis 
in the majority of newborns. Laboratory tests are more useful for excluding infection, rather 
than for identifying it. They have a high negative predicative value, but the positive predictive 
value is too low to allow for clinical decision guidance [11, 53].   
A total leucocyte count of <5000 to 7500/ mm3 can be used to infer the diagnosis of 
neonatal sepsis [53], however this test has a low predictive value and low sensibility (29%) 
[11]. Gestational age affects the leukocyte count, and so lower leukocyte number cut-offs are 
used in younger infants. This cut-off is applied only in newborns immediately after birth, since 
absolute neutrophil counts rise after birth, requiring higher cut-offs values [54]. Neutrophil’s 
absolute peak values are reached within 6-12 hours after birth, so it could be more reliable to 
obtain total leucocyte counts at this time for sepsis screening [54]. Leucopenia has shown to 
have low sensitivity and high specificity for neonatal sepsis [53], and it shouldn´t been 
forgotten that leucocyte counts may be normal in the early course of neonatal sepsis [1]. 
Immature to total neutrophil ratio ≥ 0,2 is associated with increased odds of infection, but 
conditions such perinatal asphyxia, and labor stress can also change the ratio [51]. 
Neutropenia is more predictive of neonatal sepsis than neutrophilia [53]. 
Platelets counts have no role in neonate’s sepsis diagnosis or response to treatment 
[11]. Lactate levels are predictors of death in septic shock, but it is necessary to confirm its 
predictive value in pediatric patients [55]. 
 
7.3 Acute Phase Reactants 
Procalcitonin (PCT) and C-reactive protein (CRP) are acute phase reactants, which 
levels increase due to bacterial infection or due to a range of noninfectious conditions such as 
meconium aspiration syndrome, traumatic or ischemic tissue injury or in infants with 
hemodynamic instability [1]. Viral infections are not usually associated with a raised CRP or 
PCT level [11]. Since it takes 10-12 hours for CRP levels to substantially raise after the onset 
of symptoms, peaking at 24h, it is advisable to measure CRP levels between 24-48h, 
preferably trough serial determinations to increase sensibility [56]. Due to this late increase, 
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CRP is considered a late marker of sepsis, with low sensibility when measured during the 
earlier phases [51]. 
 PCT serum concentrations rise more rapidly than CRP, peaking at 6 to 8 hours, and is 
considered a mid-phase of sepsis marker. Therefore, PCT is a more sensitive marker for early 
sepsis detection, with its levels remaining elevated for 24 hours [1]. 
Preterm infants have lower CRP baseline values and a lower rise in response to 
infection, making this laboratory marker even less sensible [57]. The normal accepted cut off 
for significant level of CRP is >6 mg/l [53]. Highly sensitive CRP is more sensitive than 
conventional CRP, having increased sensitivity for neonatal infection, but it´s role in a routine 
clinical setting still needs to be evaluated [53]. Serial normal CRP determinations have been 
shown to have a high negative predicative value, and thus repeated normal values are a 
strong sign against bacterial sepsis [56], being an indication to interrupt antibiotic therapy [7, 
58, 59].   
PCT serum concentration is not affected by gestational age, and its serum 
concentration remains high when compared to other biomarkers, making it more useful in 
predicting the severity of infection and the response to treatment [53]. However, PCT 
concentrations are affected by maternal GBS colonization and prolonged rupture of 
membranes [1]. There is a physiological increase within the first 24h of birth. The normal 
values for neonates >72 hours of age is <0,1ng/ml [57]. PCT levels decline rapidly with 
appropriate therapy and can be used to assess response to treatment, as well as in predicting 
severity of infection and outcomes [60]. Despite CRP being the most studied laboratory test in 
neonatal sepsis diagnosis, a few studies showed that PCT has better sensitivity and 
specificity than CRP [61, 62]. 
 
 7.4 Other biomarkers and diagnostic techniques  
Cytokines levels such as interleukin 6 (IL-6), IL-8, tumor necrosis factor TNF- and 
 interferon (IFN-y) rise very quickly in the setting of neonatal sepsis, even before the 
development of sepsis´s signs and symptoms and acute phase reactants [1]. They all 
generally have very similar sensitivities and speciﬁcities [11]. 
IL-6 levels peak up to 48 prior to the onset of clinical sepsis  and can be considered as 
an early and sensitive marker of neonatal infection [11]. Its levels fall quickly in response to 
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treatment due to IL-6´s short half-life, and therefore it has a narrow window of opportunity [1, 
53]. TNF- has a kinetic profile very similar to the IL-6 [63], and its levels are not affected by 
gestational or postnatal age [64].  IL-8 not only plays a role as a marker of early sepsis, but its 
levels are also associated with infection severity [65]. 
Interpretation of the combined levels of these laboratory markers, together with acute 
phase reactants is superior to the use of each one individually for the early detection of 
neonatal sepsis. This was proven for the combined use of IL-8 and CRP values [64], IL-6 and 
PCR [11] and combined IL-6, PCR and PCT levels [11]. All are highly predictive for the 
diagnosis of early onset sepsis. 
Cell surface markers such as CD11β, Scd 163 and CD64 have their expression 
increased minutes following exposure to bacterial products, and can be measured with flow 
cytometric technology, being reliable markers of early sepsis. Both sensitivity and specificity 
are very high[53]. Inflammatory biomarkers can also be searched in the amniotic fluid or in the 
cord blood for earlier sepsis detection. There is known that the presence of infection and 
inflammation in the intrauterine environment predispose the neonatal to  sepsis, but amniotic 
fluid collection is not routinely practiced for EOS detection, due to being associated with 
inherent risks [65]. Studies suggest that among cord blood biomarkers, IL-6 and IL-8 seem to 
have the best discriminatory value to early neonatal sepsis diagnosis [65]. Operational 
difficulties in cytokines detection and cell surface markers, as well as cytokines elevation in 
nonspecific settings, limit their use in clinical practice [53]. 
Quantitative real-time amplification systems (qPCR) and DNA microarray-based 
methods are another possible adjunctive diagnostic approach. Despite their high sensibility, 
and rapid results, they don´t provide information about antibiotic resistance, and they don´t 
allow distinction between true positive cases and asymptomatic colonization [65,66]. Mass 
spectrometry can aid with early identification of organisms from blood microbial cultures, 
allowing for directed antibiotic therapy, and more recently multiplex PCR can identify quickly 
common pathogens, as well as antimicrobial resistance genes [66]. 
Novel biomarkers in current investigation are haptoglobin, serum amyloid A, hepcidin, 
interα inhibitory proteins, angiopoietin 2 and soluble receptor uroquinase [53, 65]  
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8. Treatment 
Neonatal sepsis´s treatment should aim for the responsible pathogen elimination, 
maintenance of the child´s hemostasis using supporting measures, and avoidance of an 
exaggerated prejudicial inflammatory response to infection [67].  Therefore, treatment should 
offer an adequate antibiotherapy, as well as a suitable management for severe sepsis and 
septic shock that allows for preservation of vital signs and bodily functions. Consideration of 
EOS or LOS presentation affects antimicrobial choice [7]. 
8.1 Antibiotic selection 
Empiric antibiotic treatment is initiated when sepsis is suspected, based on the 
presenting clinical signs and symptoms, or, in some cases, in asymptomatic children, as is in 
the case of children born to a mother with chorioamnionitis [68]. 
The choice of the best antibiotic regimen for treatment is empirical, based on the age 
of presentation, likely etiologic agents, and local antibiotic susceptibility patterns. This last 
parameter has an increasing significance in the last few years, due to the rising prevalence 
and resistance of Gram-negative microorganisms to antibiotherapy. Empirical coverage for 
EOS should focus on the most probable etiologic agents, such as GBS and E. coli [68].  
Antibiotic classes used in neonatal sepsis´s treatment include beta-lactams (e.g.: 
penicillin, ampicillin), the glycopeptide vancomycin, aminoglycosides, such as gentamicin and 
carbapenems. Ampicillin plus gentamicin regimen is the hallmark for early neonatal sepsis 
treatment [69]. Despite the widespread use of IAP, which caused concerns about the 
development of resistance to these antibiotics, ampicillin and gentamicin are still efficient for 
most common pathogen’s treatment [51]. The strains of GBS are still susceptible to penicillin, 
ampicillin and first generation cephalosporins [14]. However, there are reports of a few 
isolated cases of GBS colonies with a higher than usual minimum inhibitory concentration to 
beta-lactams [70, 71]. 
Despite the apparently uniform GBS susceptibility to beta-lactam antibiotics, the same 
is not true for aminoglycosides, since GBS is usually resistant to this drug [69]. Nonetheless 
it´s an indispensable component in the initial therapy due to its synergic activity against GBS 
and Listeria monocytogenes when combined to ampicillin, as suggested by earlier studies 
[72]. Aminoglycoside usage, usually gentamicin, allows for inhibition of protein synthesis. 
Their use requires monitoring to achieve the correct dose and limit potential side effects [73]. 
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 There is an increasing prevalence in acquired community of extended-spectrum 
βlactamase-producing (ESBL) Gram-negative neonatal infection across the globe, and most 
of them are resistance to aminoglycosides as well [74]. The ongoing emergence of community 
ESBL-producing organisms calls for vigilance in monitoring local patterns for gentamicin´s 
susceptibility [11]. ESBL Gram-negative microorganisms are treated with carbapenems, such 
as meropenem [7]. Regarding the choice between ampicillin and penicillin, ampicillin seems 
the best choice in the absence of a etiologic diagnosis, due to its coverage to both Gram 
negative organisms, as well as the Gram positive organisms covered by penicillin [75]. Once 
GBS is identified it seems prudent to use penicillin, due to being a narrower spectrum agent, 
lowering the chances to increase other microorganisms’ antibiotic resistances [69]. 
 Third generation cephalosporins are a reasonable alternative to aminoglycosides, and 
a combination of ampicillin plus cefotaxime as an alternative therapy for empirical treatment 
has been proposed [51, 69]. However earlier studies have showed an increase in resistance 
development when cefotaxime is used routinely for neonatal sepsis treatment, especially in 
Gram negative pathogens, when compared to aminoglycosides. An increase in invasive 
candidiasis incidence has been also reported [76, 77]. If there is suspicion of meningitis while 
waiting for definitive laboratory results, cefotaxime may be added as an empirical agent [11]. 
Third and fourth generation cephalosporin drugs should be reserved for suspected Gram 
negative meningitides [7], with exception of ceftriaxone, which is not recommended when 
there is meningitis suspicion [78]. 
Regarding GBS infection specific therapy, if treatment with ampicillin and gentamicin 
was started empirically, gentamicin may be discontinued once laboratory results conﬁrm GBS 
infection. Thereafter treatment may be completed with ampicillin alone or with penicillin G. 
However, prior to narrowing it is advisable to continue to administrate ampicillin and 
gentamicin until documentation of clearance of bacteremia and CNS infection [11].In GBS´s 
neonatal meningitis cefotaxime can be administrated daily [69].  
In developing countries a ampicillin and gentamicin regimen may not be the best 
empirical antibiotic regimen of choice, due to differences in etiologic epidemiology, and should 
focus even more on individualized epidemiologic data from each hospital or region, when 
compared to developed countries [79]. LOS is empirically treated with vancomycin plus an 
aminoglycoside [12]. Doses of commonly used antibiotics in neonatal sepsis can be viewed 
on annex V. 
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8.2 Antibiotic Therapy Duration 
Antibiotic therapy´s duration for microbial cultures proven early neonatal sepsis 
depends upon the pathogen. Usually, when Gram-positive microorganisms such as GBS are 
found, therapy is administered for 14 days, while in sepsis due to Gram-negative 
microorganisms 10 days of antibiotic therapy is adequate [68]. Complicated infections need 
an extended treatment, around 21-28 days [7]. In most cases symptomatic patients with 
proven sepsis improve clinically within 48-72 hours [68]. Antibiotics should be continued for 
those who remain symptomatic and/or with positive cultures. LOS´s duration of treatment 
depends on the pathogen and site [7]. 
There is a wide variation between centers regarding the appropriate duration of 
empiric antibiotherapy for suspected early neonatal sepsis with negative blood cultures, 
because actual recommendations in this setting are not based on strong evidence  due to a 
lack of well-designed trials [79]. When considering the therapy duration in infants with 
negative blood cultures, despite presence of signs and symptoms suggestive of neonatal 
sepsis, decision should take in account clinical presentation and symptoms severity. Preterm 
infants are considered to be at high risk of sepsis, and so the usual practice is to initiate 
antibiotic therapy immediately, regardless of blood culture results if there is any degree of 
suspicion of neonatal sepsis [79]. In a retrospective study, the average duration of treatment 
in 695 infants (< 1000 g) with negative blood cultures was 5 ± 3 days [80]. 
It should be taken in account that false negative results are a possibility in pregnant 
woman who received GBS prophylaxis therapy to prevent onset of GBS infection. Decision to 
initiate therapy in culture negative sepsis (screen positive and clinical course consistent with 
sepsis) is a real challenge. The standard practice is to discontinue antibiotics as soon as 
blood cultures are conﬁrmed negative (48–72 hours), alongside absence of clinical or 
hematologic signs of infection. In this clinical situation sepsis probability is low, and prolonged 
empirical treatment of preterm infants for periods longer than five days is associated with 
higher risk of late onset sepsis, necrotizing enterocolitis, and mortality [81]. Meningitis due to 
GBS infection or other bacteria not associated with complications, should be treated for 14 
days minimum. GBS infections with a defined focus, such as osteomyelitis or endocarditis, 
should be treated for a longer time, usually for 3,4 or more weeks [51]. 
Antibiotic monitoring should be done to ensure that trough levels are adequate, and 
repeat blood cultures should be obtained, usually within 24 h of presumed effective therapy, to 
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document clearance. Persistent positive cultures could mean failure of antimicrobial therapy 
or evidence of intravascular site infection [11]. 
 
 8.3 Septic shock management 
While consensus has been reached about septic shock´s management in children and 
term neonates, there are not definitive guidelines for preterm neonate´s septic shock 
treatment [82]. 
Septic shock´s management begins with airway, breathing and circulation assessment. 
Only after vital signs stabilization, should antibiotic therapy be considered. Many septic shock 
neonates present with severe respiratory distress, and may require intubation. Initially it is 
essential to have a quickly available venous access to allow for volume resuscitation and 
vasopressor therapy whether needed, as well as for antibiotic administration. 2 venous 
accesses are recommended. When venous accesses are not immediately possible, 
intraosseous infusion or umbilical vein catheterization should be considered. Continuing 
assessment for cardiovascular dysfunction is critical [82]. 
Therapeutic endpoints are not well-defined, but it is advisable to keep a capillary refill 
less than two seconds, warm extremities, low blood lactates, urine output more than 1ml/kg/h 
and mixed venous saturation superior to 70% [ 83]. 
If hypotension is present, the first step is to give a fluid bolus, usually a crystalloid. 
However in preterm neonates there is lack of evidence regarding early volume expansion 
treatment [84], and there may be an increased risk of associated intracranial hemorrhage [82]. 
In hypotensive preterm neonates it is recommended to only give a single bolus of saline, and 
if not successful, begin therapy with vasoactive drugs as a second line approach [85]. 
Dopamine is the first choice, and if arterial tension doesn´t recover, additional therapy should 
include glucocorticoids, other catecholamine, inotropes or vasodilators [82]. Another treatment 
option for septic shock could be vasoconstrictor arginine-vasopressin, but further studies are 
needed [86]. In many clinical practices, hydrocortisone is the third-line agent in treatment of 
neonatal shock after volume resuscitation and dopamine, due to its suppression proprieties in 
the intensity of the systemic inflammatory response. Hydrocortisone has been shown to 
decrease heart rate, and decrease vasoactive medication requirements in both preterm and 
term neonates [87]. 
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 8. 4. New therapeutic strategies 
 There has been increasing research about new therapeutic approaches aiming to 
boost the neonate´s immune system, which can improve outcomes of antibiotic based 
therapy. A number of adjuvant strategies has been purposed and researched, but so far none 
of them has been successful, and are still labeled as experimental [11].  
Examples include recombinant granulocyte colony-stimulating factor (rG-CSF) and 
recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) administration, 
allowing for increased phagocytosis and cell-mediated pathogen killing. This functional benefit 
in neutrophil function was found in vitro studies, however when applied to a septic newborn, 
there wasn´t a significantly increased sepsis free survival [88]. No toxicity was observed [45]. 
Use of these agents has also been studied in a prophylactic setting, but there is also lack of 
evidence to support its application [89]. Some physicians have forgone attempts to treat 
neonatal sepsis by stimulating proliferation and function of existing neonatal neutrophil 
precursors and have instead administered adult neutrophils to at-risk neonates. A few limited 
trials have found a significant reduction on mortality [90]. More research is needed in order to 
validate this approach. 
Intravenous non-specific IVIG therapy has also been studied as an adjuvant therapy in 
neonatal sepsis, which could be especially useful in premature infants due to their profound 
IgG deficiencies. Despite favorable results in earlier smaller trials [91, 92], a recent study 
concluded that intravenous immune globulin therapy had no effect on the outcomes of 
suspected or proven neonatal sepsis [93].        
 Pentoxifylline, a drug approved for certain adult population vascular disorders, 
suppresses pro-inflammatory cytokines. It has been proposed that when combined with 
antibiotic therapy, it attenuates the inflammatory response associated with bacterial lysis, 
induced by antibiotherapy. According to a metanalysis regarding pentoxifylline use in neonatal 
sepsis, there is low-quality evidence that it is associated with a lower sepsis mortality [94]. 
More research is necessary to validate this approach.  
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9. Conclusion 
 Despite all the advances made in neonatal sepsis caused by GBS in the last decades, 
that led to a decrease in neonatal sepsis incidence, and despite the reduced mortality due to 
advancements in the neonatal critical care, the incidence of GBS neonatal sepsis is stabilizing 
without further decrease and this review demonstrated the limitations associated with current 
forms of prevention and treatment that are slowly rising. 
 An increased EOS incidence by microorganisms other than GBS, the emergence of 
antibiotics-resistant microorganism, an increased LOS incidence due to higher survival rates in 
preterm newborns and an increasing number of studies linking neonatal use of antibiotics to the 
development of autoimmune diseases, show that the status quo should not be accepted in 
regard to the current management of neonatal sepsis.  Also, despite it was observed a high 
number of studies related to etiology, diagnostic and treatment of adult sepsis, the same can´t 
be said in the pediatric population, especially regarding preterm infants, which are one of the 
groups most susceptible to neonatal sepsis. 
 This review showed that new research studies are continually being published, with 
focus on new prevention methods and more sensitive and specific laboratory markers for 
neonatal sepsis, which can have a substantial impact in the near future by leading to better 
outcomes and to less adverse effects associates with antibiotic use. Knowledge about the 
pathophysiologic events behind neonatal sepsis, and the immune system ontogeny are also 
being actively researched. The use of non-culture based diagnostics and sepsis scores to 
predict and diagnose septic neonates are areas of active investigation. Assessment of the cost-
benefit relation in these new approaches is clearly needed, due to the lack of their use in routine 
clinical practice. Concepts and attitudes standardizations about neonatal sepsis could lead to a 
more efficacious management. 
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11. ANNEXS 
  
Annex I - Global cause-specific numbers of neonatal deaths, proportions 
and risks in 2013 * 
  
 
 
   
  
*Source:  Shefali Oza et al, Neonatal cause-of-death estimates for the early and late neonatal periods for 
194 countries: 2000–2013. WHO, 2013 
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Annex II - Inflammatory response in bacterial sepsis* 
   
 
 
 
Figure 1. The Response to Pathogens, Involving “Cross-Talk” among Many Immune Cells, 
Including Macrophages, Dendritic Cells, and CD4 T Cells. 
Macrophages and dendritic cells are activated by the ingestion of bacteria and by stimulation through 
cytokines (e.g., interferon-) secreted by CD4 T cells. Alternatively, CD4 T cells that have an anti-
inflammatory profile (type 2 helper T cells [Th2]) secrete interleukin-10, which suppresses macrophage 
activation. CD4 T cells become activated by stimulation through macrophages or dendritic cells. For 
example, macrophages and dendritic cells secrete interleukin-12, which activates CD4 T cells to secrete 
inflammatory (type 1 helper T-cell [Th1]) cytokines. Depending on numerous factors (e.g., the type of 
organism and the site of infection), macrophages and dendritic cells will respond by inducing either 
inflammatory or anti-inflammatory cytokines or causing a global reduction in cytokine production (anergy). 
Macrophages or dendritic cells that have previously ingested necrotic cells will induce an inflammatory 
cytokine profile (Th1). Ingestion of apoptotic cells can induce either an anti-inflammatory cytokine profile or 
anergy. A plus sign indicates up-regulation, and a minus sign indicates down-regulation; in cases where 
both a plus sign and a minus sign appear, either up-regulation or down-regulation may occur, depending 
on a variety of factors. 
   
  
*Source: Hotchkiss et al. The pathophysiology and treatment of sepsis. N Engl J Med 348(2): 138-150, 
2003. 
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Annex III. Algorithm for GBS intrapartum prophylaxis for women with 
preterm premature rupture of membranes* 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
   
  
*Source: Enrione M, Powel K. Sepsis, Septic Shock, and Systemic Inflammatory Response Syndrome. 
Kliegman R. Nelson’s Textbook of Pediatrics (20
th
 Ed.). Saunders, 2016) 
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Annex IV. Culture-Based and Non–Culture-Based Diagnostics for Neonatal 
Sepsis* 
 
 
   
  
*Source:  Enrione M, Powel K. Sepsis, Septic Shock, and Systemic Inflammatory Response Syndrome. 
Kliegman R. Nelson’s Textbook of Pediatrics (20
th
 Ed.). Saunders, 2016) 
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Annex V - Antibiotics commonly used in pediatric practice for neonatal 
sepsis* 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
   
  
 
 
 
 
*Source:  Enrione M, Powel K. Sepsis, Septic Shock, and Systemic Inflammatory Response Syndrome. 
Kliegman R. Nelson’s Textbook of Pediatrics (20
th
 Ed.). Saunders, 2016) 
 
 
 
